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Abstract
Background Kawasaki disease is a leading cause of
acquired heart disease in children. The prevalence rate
varies in different ethnic groups. Recently, with the clinical
application of molecular genetic technology, human leu-
kocyte antigen (HLA) polymorphisms associated with
several diseases have been identiﬁed by DNA analysis.
This study aimed to assess the association of HLA alleles
with susceptibility and complications of Kawasaki disease
in Korean children.
Methods In this study, DNA was extracted from 74 chil-
dren with a diagnosis of Kawasaki disease. The
polymorphisms of the HLA-A, -B, -C, and -DRB1 alleles of
patients with Kawasaki disease were determined by poly-
merase chain reaction (PCR)–ampliﬁcation refractory
mutation system (ARMS) and PCR–sequence-speciﬁc pri-
mer (SSP) analysis. The polymorphisms identiﬁed were
comparedwiththoseof159normalhealthy controlsubjects.
Results There was a signiﬁcant increase in the frequencies
of the HLA-B35, -B75, and -Cw09 alleles in patients with
Kawasaki disease compared with the healthy control group.
There was no increase in the frequency of HLA-DRB1
alleles among the Kawasaki disease patients compared with
a healthy control group. When the patients with Kawasaki
disease were divided into two subgroups, with or without
coronary complications, the Kawasaki disease patients with
coronary complications showed a signiﬁcantly increased
frequency of the HLA-DRB1*11 allele compared with the
healthy control group and increased frequency of HLA-
DRB1*09 in a comparison of the subgroups.
Conclusions This study suggests that polymorphisms in
some alleles of B and C in HLA class I genes are associated
with Kawasaki disease in Korean children.
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Kawasaki disease is a systemic vasculitis that currently is a
leading cause of acquired heart disease in children. The
etiology of Kawasaki disease continues to be unknown,
although it was described 4 decades ago in 1967 by
Kawasaki [15]. Diagnosis continues to depend primarily on
clinical manifestations.
It appears that the pathogenesis of Kawasaki disease is
related to infection of a susceptible host coupled with
epidemiologic and ethnic factors. In a study examining the
epidemiologic characteristics of Kawasaki disease in San
Diego, CA, USA, Asians/Paciﬁc Islanders were 2.7 times
more likely and Hispanics one-third as likely to be hospi-
talized for Kawasaki disease compared with the children of
other ethnic groups combined [4]. The sibling risk ratio is
also known to be higher, than the risk of being affected
with Kawasaki disease without sibling history, and cases of
Kawasaki disease in parents and children have been
reported [10, 21].
For these reasons, many reports have suggested involve-
ment of the human leukocyte antigen (HLA) system. The
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studied. Several reports show the association of HLA geno-
types with Kawasaki disease including HLA-Bw22 (now
referred to as HLA-B54) in Japanese [14, 20], HLA-B51 in
white populations [13, 16, 18, 19], and the major histocom-
patibilitycomplexclassIchain-relatedgeneA(MICA)genes
and others in southern Chinese population [6, 12].
The major histocompatibility complex (MHC) class II
genes in Kawasaki disease show variable correlations [2, 8,
27]. To date, there have been no reports supporting a
consistent relationship between Kawasaki disease and HLA
genes in Korean patients. Therefore, the current study
aimed to assess the association of HLA-A,-B,-C, and -
DRB1 alleles with Kawasaki disease in Korean children.
Materials and Methods
Subjects
From March 2004 to December 2004, 74 patients with
Kawasaki disease (44 boys and 30 girls) attending the
pediatric outpatient clinic or admitted to St. Vincent’s
Hospital in Korea were recruited for this study. The mean
age of the patients at diagnosis was 2.7 ± 1.9 years. For
comparison, genetically unrelated healthy Korean adults
(n = 159) who had no history of Kawasaki disease were
studied as a healthy control group. Blood samples were
obtained after informed consent in compliance with the
institutional review board of St. Vincent’s hospital, College
of Medicine, The Catholic University of Korea.
The diagnosis of Kawasaki disease was established by
clinical manifestations meeting the deﬁned criteria
according to the report of the Research Committee on
Kawasaki Disease of the Japanese Ministry of Health and
Welfare in addition to exclusion of any other possible ill-
nesses [25]. Coronary complications included the
following lesions detected by echocardiography: an inter-
nal diameter exceeding 3 mm in patients younger than 5
years and exceeding 4 mm in patients age 5 years or older,
dilation of a segmental luminal diameter to at least 1.5
times that of an adjacent segment, or a deﬁnitely irregular
internal lumen of the coronary arteries. The clinical char-
acteristics of the patients are shown in Table 1.
Genomic DNA was extracted by standard methods using
the AccuPrep DNA extraction kit (Bioneer, Daejeon,
Korea) from peripheral blood collected (4 ml) with ethyl-
enediaminetetraacetic acid (EDTA) and kept at -20C.
HLA-A, -B, and -C Genotyping
The genotyping of HLA-A, -B, and -C was performed by
the ampliﬁcation refractory mutation system (ARMS)–
polymerase chain reaction (PCR) method. Each reaction
contained a primer mix consisting of the allele- or group-
speciﬁc primer pairs as well as internal control primers
matching nonallelic sequences. Speciﬁc ampliﬁcations of
the HLA-A, -B, and -C genes were performed using for-
ward and reverse primers (44 for HLA-A, 47 for HLA-B,
and 33 for HLA-C) designed according to the published
nucleotide sequences [5, 17, 26].
The PCR procedure was carried out in a reaction
(13 ll), containing 100 to 200 ng genomic DNA, 0.8 X
buffer (40 mmol/l KCl, 1.2 mmol/l MgCl2, 8 mmol/l Tris-
HCl pH 8.8, 0.08% Triton X-100), 5% dimethylsulphoxide
(DMSO), 200 lmol/l of each dNTP, 0.25 U Taq DNA
polymerase (Boehringer, Mannheim, Germany), 1 lmol/l
of each sequence-speciﬁc primer, and 0.2 lmol/l of inter-
nal control primers.
The ampliﬁcations were performed in a My Cycler
thermocycler (Bio-Rad, Hercules, USA). For ampliﬁcation,
30 cycles were performed using the following steps:
heating to 96C for 1 min to denature the DNA; denatur-
ation at 96C for 25 s and at 70C for 45 s; annealing and
extension at 72C for 30 s (for the ﬁrst 5 cycles), 96C for
25 s, 65C4 5s ,7 2 C for 30 s (for the next 21 cycles); 96C
for 25 s, 55C for 60 s, 72C for 120 s (for the last 4
cycles); and a ﬁnal 1 min extension at 72C. The presence
or absence of PCR products was determined after separa-
tion of the samples on a 1.5% agarose gel containing
0.5 lg/ml of ethidium bromide.
HLA-DRB1 Genotyping
The PCR sequence-speciﬁc primer (SSP) method was used
for HLA-DRB1 genotyping. Each reaction contained a
primer mix consisting of the allele- or group-speciﬁc pri-
mer pairs as well as the internal control primers that
matched the nonallelic sequences. Speciﬁc ampliﬁcation of
Table 1 Proﬁles of subjects with Kawasaki disease
n (%)
Male/female 44/30 (60/40)
Typical KD/atypical KD 65/9 (88/12)
Family history of KD 3 (4.1)
Recurrence history of KD 4 (5.4)
Coronary complications 21 (28)
Other complications of KD
Gallbladder hydrops 14 (19)
Pyuria 25 (34)
Hepatopathy 38 (51)
Arthritis 10 (14)
KD, Kawasaki disease
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123the HLA-DRB1 gene was performed using 47 forward and
reverse primers for HLA-DRB1 designed on the basis of
the published nucleotide sequences [23].
The PCR procedure was carried out in a reaction (10 ll)
containing 100 ng genomic DNA, 1 X buffer (60 mmol/l
Tris-HCl pH 9.0, 15 mmol/l ammonium sulphate,
2.5 mmol/l MgCl2), 200 lmol/l of each dNTP, 0.25 U Taq
DNA polymerase (Boehringer Mannheim, Germany),
1 lmol/l of each sequence-speciﬁc primer, and 0.2 lmol/l
of the internal control primers.
The ampliﬁcations performed in a My Cycler thermo-
cycler (Bio-Rad, Hercules, USA). For ampliﬁcation, 27
cycles were performed using the following steps: heating to
96C for 3 min to denature the DNA; denaturation at 96C
for 20 s; annealing and extension at 66C for 60 s (for the
ﬁrst 10 cycles), 62C for 80 s (for the next 10 cycles), and
61C for 120 s (for the last 7 cycles); and a ﬁnal 10 min
extension at 72C. The presence or absence of PCR prod-
ucts was determined after separation of samples on a 1.5%
agarose gel containing 0.5 lg/ml of ethidium bromide.
Statistical Analysis
Statistical differences between Kawasaki disease patients
and healthy control subjects and between subgroups of
Kawasaki disease patients were tested with chi-square and
Fisher’s exact test. The quantiﬁcation of the relationship of
the frequencies studied, in cases with Kawasaki disease,
was performed by calculating the relative risks using the
method of Woolf. Haldane’s modiﬁcation was applied for
cases in which the variables included zero. A p value less
than 0.05 was considered to be signiﬁcant.
In this study, the data were not adjusted for multiple
comparisons because the sample size was not large enough
for multiple-comparison analysis correction.
Results
The Genotype Distribution and Allele Frequencies of
HLA-A for the Patients With Kawasaki Disease and the
Healthy Control Group
In the analysis of the polymorphisms of HLA-A alleles, no
statistical difference was found in the frequency of alleles
between the patients with Kawasaki disease and the control
group. However, the frequency of HLA-A26 alleles was
signiﬁcantly decreased in the Kawasaki disease patients
without coronary complications (CC) compared with the
healthy control group (p\0.04; relative risk (RR) = 0.2).
In a comparison between subgroups, with and without CC,
no signiﬁcant difference was identiﬁed (Table 2).
The Genotype Distribution and Allele Frequencies of
HLA-B for the Patients With Kawasaki Disease and the
Healthy Control Group
In analysis of the polymorphisms of HLA-B alleles, there
was a signiﬁcant increase in the frequency of HLA-B35
and -B75 alleles in the patients with Kawasaki disease
compared with the control group (p\0.006; RR = 3.1 vs p
\ 0.02; RR = 8.2). When the patients with Kawasaki
disease were divided into two subgroups, with or without
CC, the Kawasaki disease patients without CC showed a
signiﬁcantly increased frequency of HLA-B35 and -B75
alleles compared with the healthy control group (p\0.02;
RR = 3.1 vs p\0.003; RR = 11) (Table 3). Although the
frequency of the HLA-B35 alleles were similar in the
groups with and without CC (19% vs 18.9%), the HLA-
B75 allele was found only in the Kawasaki disease patients
without CC (0.0% vs. 13.2%). Therefore, the HLA-B35
allele was implicated in susceptibility to Kawasaki disease
Table 2 The allele frequencies
of human leukocyte antigen-A
(HLA-A) in the patients with
Kawasaki disease and the
control subjects
KD, Kawasaki disease; RR,
relative risk
a p\0.04; RR = 0.2 (95%
conﬁdence interval [CI], 0.05–
0.90) vs healthy control subjects
HLA alleles Healthy controls
(n =159) n (%)
KD patients
(n = 74) n (%)
Coronary complications
Present (n = 21) n (%) Absent (n =5 3n (%)
HLA-A
01 5 (3.1) 5 (6.8) 2 (9.5) 3 (5.7)
02 85 (53.5) 43 (58.1) 12 (57.1) 31 (58.5)
03 5 (3.1) 3 (4.1) 0 (0.0) 3 (5.7)
11 31 (19.5) 21 (28.4) 6 (28.6) 15 (28.3)
24 57 (35.8) 33 (44.6) 12 (57.1) 21 (39.6)
26 25 (15.7) 6 (8.1) 4 (19.0) 2 (3.8)
a
30 20 (12.6) 4 (5.4) 1 (4.8) 3 (5.7)
31 14 (8.8) 6 (8.1) 0 (0.0) 6 (11.3)
32 3 (1.9) 0 (0.0) 0 (0.0) 0 (0.0)
33 38 (23.9) 15 (20.3) 2 (9.5) 13 (24.5)
68 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0)
404 Pediatr Cardiol (2008) 29:402–408
123and the HLA-B75 allele in susceptibility to Kawasaki
disease without CC. In a comparison between the sub-
groups, with and without CC, there was no overall
signiﬁcant difference identiﬁed between the two groups.
The Genotype Distribution and Allele Frequency of
HLA-C for the Patients With Kawasaki Disease and the
Healthy Control Group
In the analysis of the polymorphisms of HLA-C alleles,
there was a signiﬁcant increase in the frequency of the
HLA-Cw09 allele in the patients with Kawasaki disease
compared with the healthy control group (p\0.04; RR =
2.0). When the Kawasaki disease patients were divided into
two subgroups, with or without CC, the Kawasaki disease
patients without CC showed a signiﬁcantly increased fre-
quency of the HLA-Cw09 allele compared with the healthy
control group (p \ 0.05; RR = 2.1). However, no
signiﬁcant difference was found between the subgroups
with and without CC (Table 4).
The Genotype Distribution and the Allele Frequencies
of HLA-DRB1 for the Patients With Kawasaki Disease
and the Healthy Control Group
Among the HLA-DRB1 alleles, there was no increase in the
frequency of alleles in the Kawasaki disease patients com-
pared with the healthy control group. However, after
subgrouping of the Kawasaki disease patients, with or
without CC, the frequency of HLA-DRB1*11 was signiﬁ-
cantly increased in the Kawasaki disease patients with CC
compared with the healthy control group (p\0.04; RR =
4.7). In a comparison between the subgroups, with and
without CC, the frequency of the HLA-DRB1*09 allele was
increased in the Kawasaki disease patients with CC com-
paredwiththeKawasakidiseasepatientswithoutCC(33.3%
Table 3 The allele frequencies
of human leukocyte antigen-B
(HLA-B) in the patients with
Kawasaki disease and the
control subjects
KD, Kawasaki disease; RR,
relative risk
a p\0.006; RR = 3.1 (95%
conﬁdence interval [CI], 1.29–
7.62) vs healthy control subjects
b p\0.02; RR = 3.1 (95% CI,
1.16–8.43) vs healthy control
subjects
c p\0.02; RR = 8.2 (95% CI,
1.74–38.68) vs healthy control
subjects
d p\0.003; RR = 11 (95% CI,
2.79–51.13) vs healthy control
subjects
HLA alleles Healthy controls
(n = 159) n (%)
KD patients
(n = 74) n (%)
Coronary complications
Present (n = 21) n (%) Absent (n = 53) n (%)
HLA-B
07 19 (11.9) 9 (12.2) 3 (14.3) 6 (11.3)
08 2 (1.3) 0 (0.0) 0 (0.0) 0 (0.0)
13 20 (12.6) 5 (6.8) 2 (9.5) 3 (5.7)
14 6 (3.8) 0 (0.0) 0 (0.0) 0 (0.0)
27 11 (6.9) 3 (4.1) 1 (4.8) 2 (3.8)
35 11 (6.9) 14 (18.9)
a 4 (19.0) 10 (18.9)
b
37 5 (3.1) 4 (5.4) 2 (9.5) 2 (3.8)
38 7 (4.4) 3 (4.1) 0 (0.0) 3 (5.7)
39 2 (1.3) 3 (4.1) 2 (9.5) 1 (1.9)
44 29 (18.2) 10 (13.5) 3 (14.3) 7 (13.2)
46 18 (11.3) 7 (9.5) 2 (9.5) 5 (9.4)
47 0 (0.0) 1 (1.4) 0 (0.0) 1 (1.9)
48 13 (8.2) 2 (2.7) 0 (0.0) 2 (3.8)
51 29 (18.2) 13 (17.6) 5 (23.8) 8 (15.1)
52 9 (5.7) 3 (4.1) 2 (9.5) 1 (1.9)
54 23 (14.5) 10 (13.5) 3 (14.3) 7 (13.2)
55 3 (1.9) 4 (5.4) 1 (4.8) 3 (5.7)
56 2 (1.3) 0 (0.0) 0 (0.0) 0 (0.0)
57 2 (1.3) 1 (1.4) 0 (0.0) 1 (1.9)
58 15 (9.4) 5 (6.8) 0 (0.0) 5 (9.4)
59 4 (2.5) 3 (4.1) 0 (0.0) 3 (5.7)
60 11 (6.9) 7 (9.5) 2 (9.5) 5 (9.4)
61 23 (14.5) 13 (17.6) 6 (28.6) 7 (13.2)
62 29 (18.2) 14 (18.9) 1 (4.8) 13 (24.5)
67 4 (2.5) 2 (2.7) 1 (4.8) 1 (1.9)
71 7 (4.4) 1 (1.4) 0 (0.0) 1 (1.9)
75 2 (1.3) 7 (9.5)
c 0 (0.0) 7 (13.2)
d
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123vs 9.4%; p\0.04). However, there was no signiﬁcant dif-
ference in the frequency of these alleles when each was
compared with the healthy control group. The frequency of
the HLA-DRB1*04 allele was slightly increased in the Ka-
wasaki disease patients without CC compared with the
healthy control group (p\0.05; RR = 1.9) (Table 5).
Discussion
The prevalence of CC among the patients with Kawasaki
disease in this study was higher than previously reported
(28.4% vs 5%) [22]. This is likely because the patients
included had a previous diagnosis of Kawasaki disease and
were attending our clinic for this reason. Patients with
more severe Kawasaki disease, including those with CC,
present for medical care more frequently than patients
without CC, and this may explain the higher proportion of
CC in our study. Three patients (4%) had a positive family
history, and four patients (5.4%) had a history of Kawasaki
disease recurrence. Prior studies reported the familial
occurrence and recurrence rates for Kawasaki disease to be
1% and 3%, respectively [11, 24, 28].
Our data were conﬁned to Korean children and focused
on patients who had Kawasaki disease with CC. Therefore,
further research on the effect of the family history and
recurrence of Kawasaki disease in association with HLA
polymorphisms is needed.
Studies have associated HLA alleles with many different
human diseases, such as HLA-B27 with ankylosing
Table 4 The allele frequencies
of human leukocyte antigen-C
(HLA-C) in the patients with
Kawasaki disease and the
control subjects
KD, Kawasaki disease; RR,
relative risk
a p\0.04; RR = 2.0 (95%
conﬁdence interval [CI], 0.97–
4.29) vs healthy control subjects
b p\0.05; RR = 2.1 (95% CI,
0.92–4.87) vs healthy control
subjects
HLA alleles Healthy controls
(n = 159) n (%)
KD patients
(n = 74) n (%)
Coronary complications
Present (n = 21) n (%) Absent (n = 53) n (%)
HLA-Cw
01 59 (37.1) 22 (29.7) 6 (28.6) 16 (30.2)
02 0 (0.0) 1 (1.4) 0 (0.0) 1 (1.9)
04 21 (13.2) 11 (14.9) 2 (9.5) 9 (17.0)
05 6 (3.8) 1 (1.4) 0 (0.0) 1 (1.9)
06 25 (15.7) 10 (13.5) 5 (23.8) 5 (9.4)
07 44 (27.7) 20 (27.0) 6 (28.6) 14 (26.4)
08 29 (18.2) 10 (13.5) 3 (14.3) 7 (13.2)
09 23 (14.5) 19 (25.7)
a 5 (23.8) 14 (26.4)
b
10 39 (24.5) 24 (32.4) 5 (23.8) 19 (35.8)
12 11 (6.9) 4 (5.4) 2 (9.5) 2 (3.8)
14 34 (21.4) 18 (24.3) 7 (33.3) 11 (20.8)
15 8 (5.0) 1 (1.4) 1 (4.8) 0 (0.0)
Table 5 The allele frequencies
of human leukocyte antigen-
DRB1 (HLA-DRB1) in the
patients with Kawasaki disease
and the control subjects
KD, Kawasaki disease; RR,
relative risk
a p\0.05; RR = 1.9 (95%
conﬁdence interval [CI], 0.96–
3.82) vs healthy control subjects
b p\0.04 between KD patients
with and without coronary
complication
c p\0.04; RR = 4.7 (95% CI,
1.26–17.17) vs healthy control
subjects
HLA alleles Healthy controls
(n = 159) n (%)
KD patients
(n = 74) n (%)
Coronary complications
Present (n = 21) n (%) Absent (n = 53) n (%)
HLA-DRB1
01 29 (18.2) 8 (10.8) 1 (4.8) 7 (13.2)
03 7 (4.4) 1 (1.4) 0 (0.0) 1 (1.9)
04 48 (30.2) 30 (40.5) 6 (28.6) 24 (45.3)
a
07 26 (16.4) 8 (10.8) 1 (4.8) 7 (13.2)
08 32 (20.1) 14 (18.9) 3 (14.3) 11 (20.8)
09 28 (17.6) 12 (16.2) 7 (33.3)
b 5 (9.4)
10 4 (2.5) 4 (5.4) 2 (9.5) 2 (3.8)
11 10 (6.3) 8 (10.8) 5 (23.8)
c 3 (5.7)
12 18 (11.3) 11 (14.9) 2 (9.5) 9 (17.0)
13 32 (20.1) 10 (13.5) 3 (14.3) 7 (13.2)
14 21 (13.2) 10 (13.5) 3 (14.3) 7 (13.2)
15 35 (22.0) 20 (27.0) 5 (23.8) 15(28.3)
16 4 (2.5) 2 (2.7) 1 (4.8) 1 (1.9)
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123spondylitis and Reiter syndrome, HLA-B35 with subacute
thyroiditis, and HLA-DR8 with juvenile rheumatoid
arthritis. Most of the early studies on the genetics of
Kawasaki disease were conducted using serologic testing
that measured HLA antigens. The association of the HLA-
Bw22 allele with Kawasaki disease in Japanese studies was
evaluated with the microcytotoxicity test used for tissue
typing of 205 patients with Kawasaki disease and 500
control samples in the late 1970s [14]. On basis of these
studies, a gene was thought to control susceptibility to
Kawasaki disease and was linked to the Japanese-speciﬁc
HLA antigen.
Since the clinical application of genetic technology
became available in the 1980s, polymorphisms at many
HLA loci have been identiﬁed. In addition, there were
changes in nomenclature, and the alleles were reclassiﬁed.
For example, the previously labeled HLA-Bw22 allele was
changed to the HLA B54 allele [1, 3].
Our study on the polymorphisms of HLA genes was
conducted using the PCR-ARMS method for the HLA
class I genes and the PCR-SSP method for the HLA class II
genes. There was a signiﬁcant increase in the frequencies
of HLA-B35, -B75, and -Cw09 alleles in the patients with
Kawasaki disease compared with the healthy control group.
As previously mentioned, this study showed that the HLA-
B35 allele was related to susceptibility to Kawasaki disease
and the HLA-B75 allele to Kawasaki disease without CC in
Korean children. These results suggest that polymorphisms
(in some of the B and C loci) in HLA class I genes are
associated with Kawasaki disease in Korean children;
consistent with prior reports on other ethnic groups [12, 14,
16, 19].
Review of the medical literature on Kawasaki disease
and HLA shows that there is a trend toward an association
between the HLA-B loci and Kawasaki disease. However,
to date, there is no conﬁrmed relationship to a particular
locus. It is likely that the HLA-B locus is not the only locus
associated with Kawasaki disease. This can be the case
because of its functional variation or the potential effects
from other related genes around the HLA-B locus. The
HLA-B locus and other associated genes might be useful
genetic markers for Kawasaki disease.
The HLA-B35 gene is known to play a major role in a
variety of infections. For example, in cases with HIV
infection, the patients with an increased frequency of HLA-
B35 show rapid progression of HIV [9]. Infection has been
implicated in the etiology of Kawasaki disease. The ﬁnding
in our study that the frequency of the HLA-B35 allele was
increased in Korean children with Kawasaki disease sug-
gests a role for infection in Kawasaki disease.
The HLA-DRB1 alleles showed no increased frequency
in the Kawasaki disease patients compared with the healthy
control group. However, when the patients were compared
by subgroups, with and without CC, the frequency of HLA-
DRB1*11 was signiﬁcantly increased in the Kawasaki
disease patients with CC (p\0.04; RR = 4.7), and HLA-
DRB1*04 was increased in the Kawasaki disease patients
without CC (p\0.05; RR =1.9) compared with the healthy
control group. Comparison of the subgroups with and
without CC showed that the frequency of the HLA-
DRB1*09 allele was increased in Kawasaki disease
patients with CC compared with the Kawasaki disease
patients who had no CC (33.3% vs 9.4%; p \ 0.04), and
that there was no signiﬁcant difference in comparison with
the healthy control group. For the HLA-DRB1*11 allele,
the ﬁnding of a higher allele frequency compared with the
healthy control group was ampliﬁed by the subgrouping of
Kawasaki disease patients with and without CC. Future
studies with a larger sample size are needed to conﬁrm
these ﬁndings.
Several reports describe the presence of HLA-DRB1
and the progression of infections [7]. However, most of the
reports on the association of HLA-DRB1 with Kawasaki
disease concluded that despite a regional association, their
data failed to support a consistent role for HLA class II
alleles in Kawasaki disease. If there was any role, it was
predicted to be minor [2, 8].
Interpopulation discrepancies of the frequencies of HLA
alleles make generalization of results difﬁcult. Matched
population proﬁles are needed for disease association
studies because ethnic differences can provide altered
disease associations.
In this study, we compared HLA alleles of Kawasaki
disease patients with known polymorphic loci of HLA
genes in healthy Korean adults. The results we report on
the polymorphisms of HLA genes in Kawasaki disease
patients may be limited to the Korean population. How-
ever, this information may be helpful in future studies on
HLA genetic polymorphisms in Kawasaki disease. Further
studies with a larger sample size are needed for conﬁr-
mation of our ﬁndings.
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